In silico analysis and experimental validation shows negative correlation between miR-1183 and cell cycle progression gene 1 expression in colorectal cancer.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
04
2023
accepted:
11
07
2023
medline:
7
8
2023
pubmed:
4
8
2023
entrez:
4
8
2023
Statut:
epublish
Résumé
MicroRNAs (miRNAs) are small noncoding RNAs that post-transcriptionally regulate gene expression by binding to the 3' untranslated regions (UTR) of target genes. Aberrant expression of miRNAs can lead to disease, including cancer. Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide. Among several factors, differential expression of miRNA can have serious consequences on disease progression. This study was designed to computationally identify and experimentally verify strong miRNA candidates that could influence CRC progression. In silico analysis of publicly available gene expression microarray datasets revealed significant upregulation of miR-1183 in CRC. Comparison of mRNA microarray expression data with predicted miR-1183 targets led to the identification of cell cycle progression gene 1 (CCPG1) as strong, negatively correlated miR-1183 target. Expression analysis by means of quantitative PCR validated the inverse correlation between miR-1183 and CCPG1 in colorectal cancer tissues. CCPG1 indirectly modulates the cell cycle by interacting with the PH/DH domain of Dbs (Rho-specific guanine nucleotide exchange factor). Interestingly, the computational analysis also showed that miR-1183 is upregulated in liver and gastric cancer. This finding is notable as the liver and stomach are the primary metastatic sites for colorectal cancer and hepatocellular carcinoma respectively. This novel finding highlights the broader implications of miR-1183 dysregulation beyond primary CRC, potentially serving as a valuable prognostic marker and a therapeutic target for both primary and metastatic CRC.
Identifiants
pubmed: 37540697
doi: 10.1371/journal.pone.0289082
pii: PONE-D-23-09843
pmc: PMC10403070
doi:
Substances chimiques
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0289082Informations de copyright
Copyright: © 2023 Fatima et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
World J Gastroenterol. 2014 Sep 14;20(34):12241-8
pubmed: 25232258
Front Oncol. 2020 Dec 09;10:607909
pubmed: 33363037
Childs Nerv Syst. 2018 Mar;34(3):417-422
pubmed: 29247256
Exp Ther Med. 2013 Mar;5(3):902-906
pubmed: 23408108
Tumour Biol. 2014 Oct;35(10):9787-92
pubmed: 24981248
Anticancer Res. 2010 Oct;30(10):4157-61
pubmed: 21036735
HPB (Oxford). 2012 Mar;14(3):209-15
pubmed: 22321040
Transl Oncol. 2021 Oct;14(10):101174
pubmed: 34243011
HPB (Oxford). 2006;8(2):89-92
pubmed: 18333252
Int J Mol Sci. 2016 Jun 03;17(6):
pubmed: 27271613
Mol Cells. 2011 Sep;32(3):243-9
pubmed: 21887509
Sci Rep. 2016 Feb 08;6:20616
pubmed: 26852921
World J Surg. 1995 Jan-Feb;19(1):59-71
pubmed: 7740812
Mol Med Rep. 2017 Oct;16(4):5241-5248
pubmed: 28849155
Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1113-9
pubmed: 22172905
RNA. 2008 Nov;14(11):2348-60
pubmed: 18812439
BMC Mol Biol. 2017 Aug 23;18(1):22
pubmed: 28835206
Exp Cell Res. 2015 Jan 15;330(2):423-428
pubmed: 25128149
Nucleic Acids Res. 2015 Jan;43(Database issue):D1113-6
pubmed: 25361974
Am J Transl Res. 2010 Sep 28;3(1):28-47
pubmed: 21139804
Nucleic Acids Res. 2016 Jul 8;44(W1):W147-53
pubmed: 27190236
Prz Gastroenterol. 2019;14(2):89-103
pubmed: 31616522
Ann Surg. 2002 Jan;235(1):86-91
pubmed: 11753046
PLoS One. 2014 Dec 30;9(12):e115293
pubmed: 25548906
Eur J Pharmacol. 2019 Jul 5;854:298-306
pubmed: 30980798
Dig Liver Dis. 2012 Mar;44(3):195-200
pubmed: 22105087
Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5
pubmed: 23193258
Biol Pharm Bull. 2018;41(4):604-611
pubmed: 29607933
Cancer Immunol Immunother. 2021 Nov;70(11):3261-3275
pubmed: 33837850
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Cell. 2018 Mar 22;173(1):20-51
pubmed: 29570994
Med Sci Monit. 2015 Mar 03;21:667-73
pubmed: 25731670
J Natl Cancer Inst. 2013 Jun 19;105(12):849-59
pubmed: 23704278
Life Sci. 2019 Mar 15;221:354-361
pubmed: 30811964
Molecules. 2014 May 13;19(5):6047-57
pubmed: 24828377
Nucleic Acids Res. 2012 Dec;40(22):11673-83
pubmed: 23034802
Growth Factors. 2015;33(5-6):384-92
pubmed: 26653968
Nucleic Acids Res. 2018 Jan 4;46(D1):D754-D761
pubmed: 29155950
Mol Cell Biol. 2006 Dec;26(23):8964-75
pubmed: 17000758
Lancet Oncol. 2005 Nov;6(11):871-6
pubmed: 16257795
PLoS One. 2011;6(10):e26971
pubmed: 22066022
Cancer Lett. 2015 May 1;360(2):151-9
pubmed: 25662441
J Cancer Res Clin Oncol. 2011 Apr;137(4):557-66
pubmed: 20508945
Elife. 2015 Aug 12;4:
pubmed: 26267216